Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.20

-5.5%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (7801)	3/10/2003 11:31:43 AM
From: JMarcus	Read Replies (1) of 52153

EPIX received a favorable mention in Dr. Ron Garren's private newsletter, biotechinsight.com, as follows: <<The results of the second Phase III vascular imaging trial announced Friday by Epix Medical (EPIX) clearly seems to show they have a great MRI vascular imaging agent. The technology basically uses a standard a MRI contrast agent modified so that it binds to albumin, a circulating protein. This keeps the agent (MS-325) inside the vascular tree allowing almost anatomic imaging of vascular problems. It looks as good as the gold standard, which is IV contrast angiography but without the downsides of potential kidney damage, bleeding and allergic reactions. EPIX with a market cap of approximately $127 million looks cheap for a company that may set a new standard of care. Management expects the final two Phase III trials to report this summer and a possible filing in the fall of ¡¦03. If and when MRI technology gets up to speed for cardiovascular imaging this could open another huge market. The company is in partnership with Schering AG in the US and gets royalties from the rest of the world. I just bought some for my personal account.>> Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next